Cytokine modulation by etanercept ameliorates metabolic syndrome and its related complications induced in rats administered a high-fat high-fructose diet
Open Access
- 23 November 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 12 (1), 1-14
- https://doi.org/10.1038/s41598-022-24593-9
Abstract
The aim of the present study was to investigate the effect of etanercept (ETA)—an anti-tumor necrosis factor α (TNF-α) monoclonal antibody—on metabolic disorders such as obesity, hypertension, dyslipidemia, and insulin resistance associated with the metabolic syndrome (MS). MS was induced in rats via high-fat high-fructose (HFHF) administration for 8 weeks. Rats were divided into three groups: negative control, HFHF model, and ETA-treated groups [HFHF + ETA (0.8 mg/kg/twice weekly, subcutaneously) administered in the last 4 weeks]. ETA effectively diminished the prominent features of MS via a significant reduction in the percent body weight gain along with the modulation of adipokine levels, resulting in a significant elevation of serum adiponectin consistent with TNF-α and serum leptin level normalization. Moreover, ETA enhanced dyslipidemia and the elevated blood pressure. ETA managed the prominent features of MS and its associated complications via the downregulation of the hepatic inflammatory pathway that induces nonalcoholic steatohepatitis (NASH)—from the expression of Toll-like receptor 4, nuclear factor kappa B, and TNF-α until that of transforming growth factor—in addition to significant improvements in glucose utilization, insulin sensitivity, and liver function parameter activity and histopathological examination. ETA was effective for the treatment of all prominent features of MS and its associated complications, such as type II diabetes mellitus and NASH.Funding Information
- Modern Academy for Technology, Computer Science & Management
This publication has 69 references indexed in Scilit:
- Association between Serum Leptin Concentrations and Insulin Resistance: A Population-Based Study from ChinaPLOS ONE, 2013
- Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistanceArthritis Research & Therapy, 2012
- Inflammation and Increased Aromatase Expression Occur in the Breast Tissue of Obese Women with Breast CancerCancer Prevention Research, 2011
- TNF-α Antagonism with Etanercept Decreases Glucose and Increases the Proportion of High Molecular Weight Adiponectin in Obese Subjects with Features of the Metabolic SyndromeJournal of Clinical Endocrinology & Metabolism, 2011
- Health implications of fructose consumption: A review of recent dataNutrition & Metabolism, 2010
- Present and future therapeutic strategies in non-alcoholic fatty liver diseaseEmerging Therapeutic Targets, 2007
- High-fat emulsion-induced rat model of nonalcoholic steatohepatitisLife Sciences, 2006
- Effects of Etanercept in Patients With the Metabolic SyndromeArchives of Internal Medicine, 2006
- Design and validation of a histological scoring system for nonalcoholic fatty liver diseaseJournal of Hepatology, 2005
- How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACHInternational Journal of Cardiology, 2002